Compare NPK & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPK | MGTX |
|---|---|---|
| Founded | 1905 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 881.7M |
| IPO Year | 1994 | 2018 |
| Metric | NPK | MGTX |
|---|---|---|
| Price | $139.20 | $9.21 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $27.75 |
| AVG Volume (30 Days) | 95.4K | ★ 607.2K |
| Earning Date | 11-24-2026 | 11-12-2026 |
| Dividend Yield | ★ 0.71% | N/A |
| EPS Growth | N/A | ★ 33.02 |
| EPS | ★ 0.99 | 0.68 |
| Revenue | ★ $503,524,000.00 | $81,391,000.00 |
| Revenue This Year | N/A | $314.19 |
| Revenue Next Year | $10.60 | N/A |
| P/E Ratio | $142.82 | ★ $12.97 |
| Revenue Growth | 29.70 | ★ 144.57 |
| 52 Week Low | $91.28 | $6.62 |
| 52 Week High | $158.17 | $15.35 |
| Indicator | NPK | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 37.58 | 43.56 |
| Support Level | $134.69 | $8.80 |
| Resistance Level | $147.26 | $10.08 |
| Average True Range (ATR) | 4.44 | 0.53 |
| MACD | -1.01 | 0.08 |
| Stochastic Oscillator | 6.94 | 49.03 |
National Presto Industries Inc has an electric product portfolio consisting of household appliances, ammunition, and diapers. The company operates in three segments, namely Defense, Housewares/Small Appliance, and Safety. The defense segment, which is engaged in manufacturing 40mm ammunition, precision mechanical and electro-mechanical assemblies, and medium caliber cartridge cases, performs Load, Assemble, and Pack (LAP) operations on ordnance-related products for the U.S. Government and prime contractor. While the Housewares/Small Appliance segment designs, markets, and distributes housewares and small electrical appliances, the safety segment provides safety technology empowering organizations and individuals to protect what is more important.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.